London
11 °C
Manchester
10 °C
Glasgow
7 °C
Dublin
9 °C
Belfast
Washington
Denver
Atlanta
Dallas
Houston Texas
17 °C
New Orleans
El Paso
Phoenix
Los Angeles
11 °C
-13 °C
22 °C
32 °C
22 °C
13 °C
Tharimmune to Present at the Microcap Conference 2025
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| RBGPF | -2.23% | 80.22 | $ | |
| BCC | 0.59% | 76.29 | $ | |
| CMSC | -0.34% | 23.26 | $ | |
| NGG | 1.8% | 77.16 | $ | |
| JRI | -0.6% | 13.43 | $ | |
| RIO | 1.55% | 77.19 | $ | |
| RYCEF | 1.48% | 14.86 | $ | |
| CMSD | -0.43% | 23.28 | $ | |
| VOD | 0.86% | 12.81 | $ | |
| BCE | -0.78% | 23.15 | $ | |
| RELX | -0.64% | 40.56 | $ | |
| BTI | -0.21% | 57.17 | $ | |
| GSK | -0.14% | 48.71 | $ | |
| BP | 2.06% | 34.47 | $ | |
| AZN | -1.66% | 89.86 | $ |
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
H.O.Scholz--BlnAP
